AstraZeneca Pharma India Ltd to launch Palivizumab in India

AstraZeneca Pharma India Limited will launch Palivizumab (Synagis) in October 2024 in India.

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:

- Infants born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.

- Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia (BPD) within the last 6 months.

- Children less than 2 years of age and with hemodynamically significant congenital heart disease (CHD).

The company received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Palivizumab (Synagis) solution for injection 100 mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL presentations in single-dose vials administered through intramuscular route) on Sep 30, 2023.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 6728.00 as compared to the previous close of Rs. 6703.00. The total number of shares traded during the day was 327 in over 188 trades.

The stock hit an intraday high of Rs. 6786.00 and intraday low of 6550.00. The net turnover during the day was Rs. 2183134.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Palivizumab Synagis IndiaLaunch